medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2008, Number 1

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2008; 6 (1)

Keratoachantoma's epidemiology at the “Dr. Manuel Gea González” General Hospital

Vera IDS, Narváez RV, Rangel GL, Tousaint CS, Fonte ÁV, Domínguez CJ

Language: Spanish
References: 13
Page: 8-14
PDF size: 342.87 Kb.


ABSTRACT

Background: Keratoacanthoma is a common, rapidly growing skin lesion with a distinctive appearance and clinical course; it is also regarded as a low-grade or abortive squamous cell carcinoma.
Objective: To obtain the epidemiologic features of keratoacanthoma with their clinical and histological characteristics in population attending at the Service of Dermatology at the “Dr. Manuel Gea González” General Hospital.
Material and Methods: This is a transversal, retrospective, descriptive and observational study of keratoacanthoma in a General Hospital from 1994 to 2007. Descriptive statistics were used.
Results: We found twenty eight patients, fifteen females and thirteen males. The age ranged from 24 to 82 years, fifteen of them were located in the face, eleven in extremities and two in trunk.
Conclusions: Keratoacanthoma is a squamous cell carcinoma of rapid grow, present in both sexes and mainly affecting face and limbs.


REFERENCES

  1. Reyes, M., G. Romero, H. Alcántara et al., “Caracterización epidemiológica y concordancia clínico-patológica del cáncer de piel en el Hospital ‘Dr. Manuel Gea González’”, DCMQ. 2007; 5 (2): 80-87.

  2. Yuge, S., D. Santos Godoy, M. Coelho de Melo et al., “Kera to acan tho - ma centrifugum marginatum: Response to topical 5-fluorouracil”, J. Am. Acad. Dermatol. 2006; 54: S218-219.

  3. Blasco, J., R. Ruiz, R. Naranjo et al., “Queratoacantoma solitario. Respuesta a imiquimod 5% en crema”, Dermatol. Cosmet. 2001; 11 (4): 149-152.

  4. Kerschmann, R., T. McCalmont y E. LeBoit E, “p53 Oncoprotein Expression and Proliferation Index in Keratoacanthoma and Squamous Cell Carcinoma”, Arch. Dermatol. 1994; 130: 181-186.

  5. Paniker, P., “Diagnosing solitary keratoacanthomas”, Am. J. of Med. 2005; 118: 19.

  6. Arenas, R., “Queratoacantoma”, en Atlas dermatología. Diagnóstico y tratamiento, 3a ed., McGraw Hill, 570-571.

  7. Alcalá, D., R. Gutiérrez, R. M. Gutiérrez et al., “Queratoacantoma. Comunicación de un caso”, Rev. Cent. Dermatol. Pascua. 2003; 12 (3): 126-130.

  8. Ferraz de Arruda Veiga, T., A. Moraes, A. Martins et al., “Que ra to a - cantoma gigante: relato de un caso”, Med. Cutan. Iber. Lat. Am. 2004; 32 (2): 75-77.

  9. Esser, A., A. Abril, S. Fayne et al., “Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab”, J. Am. Acad. Dermatol. 2004; 50: S75-77.

  10. Ujiie, H., N. Kato, K. Natsuga et al, “Keratoacanthoma developing on nevus sebaceous in a child”, J. Am. Acad. Dermatol. 2006; 56: S57-S58.

  11. Goldberg, L., S. Silapunt, K. Beyrau et al., “Keratoacanthoma as a postoperative complication of skin cancer excision”, J. Am. Acad. Dermatol. 2004; 50: 753-758.

  12. Cain, C., T. Niemann y Z. Argenyi, “Keratoacanthoma Versus Squamous Cell Carcinoma. An Immunohistochemical Reapprasial of p53 Protein and Proliferating Cell Nuclear Antigen Expression in Keratoacanthoma-Like Tumors”, Am. J. Dermatopathol. 1995; 17 (4): 324-331.

  13. LeBoit, P., “Can We Understand Keratoacanthoma?”, Am. J. Dermatopathol. 2002; 24 (2): 166-168.




2020     |     www.medigraphic.com